Johnson & Johnson (NYSE:JNJ) Stock Price Down 0.8% - Here's Why

Shares of Johnson & Johnson (NYSE:JNJ) declined by 0.8% during trading on Monday, reaching a low of $163.23 before stabilizing at $163.77. In total, 1,249,891 shares were exchanged, significantly lower than the average daily volume of 7,001,170 shares. The stock had closed the previous session at $165.12.

Analysts' Insights on JNJ

Several analysts have recently shared their views on Johnson & Johnson. On October 16th, Morgan Stanley increased their price target from $169.00 to $175.00, maintaining an "equal weight" rating on the stock. In a separate report, StockNews.com upgraded the stock from a "buy" to a "strong buy" rating on September 14th. However, the Goldman Sachs Group decreased their target from $160.00 to $155.00, citing a "neutral" stance on the company as of July 19th. TD Cowen also lowered their target from $195.00 to $185.00 during the same period while keeping a "buy" recommendation. Meanwhile, Wells Fargo raised their target from $163.00 to $166.00, also assigning an "equal weight" rating on October 16th. According to MarketBeat, the stock holds a "Moderate Buy" rating with an average price target of $175.93 based on contributions from various analysts.

Latest Trading Performance

During this trading session, shares of Johnson & Johnson experienced a noticeable decline of 1.2%. The company’s financial indicators show a debt-to-equity ratio of 0.44 and a current ratio of 1.07, with a quick ratio of 0.85. Additionally, the stock's 50-day moving average is $162.98 while the 200-day moving average sits at $154.69. The company currently holds a market capitalization of $392.70 billion and a price-to-earnings ratio (P/E) of 10.21, complemented by a P/E growth ratio (P/E/G) of 2.65, highlighting moderate growth potential. Furthermore, its beta is measured at 0.52, indicating lower volatility compared to the broader market.

Dividend Announcement

Johnson & Johnson has also announced a quarterly dividend, which is set to be paid on December 10th. Shareholders registered on or before November 26th will receive a dividend amounting to $1.24 per share. This dividend translates to an annualized total of $4.96, reflecting a 3.04% yield. The company's current dividend payout ratio is approximately 30.92%.

Insider Trading Activity

In recent insider transactions, Vice President Robert J. Decker sold 5,635 shares on August 30th at an average price of $165.06, amounting to a total of $930,113.10. After this transaction, he retains ownership of 18,973 shares valued at roughly $3,131,683.38. Such insider trading activities are disclosed via formal filings with the SEC, which are available for public viewing. Interestingly, corporate insiders hold approximately 0.16% of the company’s total shares.

Institutional Investment Trends

Recent changes in institutional investments highlight an active interest in Johnson & Johnson. Innealta Capital LLC and MFA Wealth Advisors LLC each established new holdings in the company, with respective valuations of around $27,000 and $43,000 during the second quarter. Additionally, Fairway Wealth LLC increased their position in Johnson & Johnson by an impressive 217.1%. These institutional investments portray confidence among major stakeholders, as approximately 69.55% of JNJ's shares are currently held by institutional investors.

About Johnson & Johnson

Johnson & Johnson, along with its subsidiaries, is dedicated to researching, developing, manufacturing, and selling a diverse range of healthcare products globally. Its Innovative Medicine segment covers a variety of therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular health, offering products distributed through various channels.

Stock, Price, Analysts